Drug resistance remains a central barrier to durable responses across cancer therapies, spanning targeted agents, cytotoxic chemotherapy, endocrine ...

Current AGI research focuses heavily on scaling these foundation models and enhancing specific agent capabilities, such as complex reasoning and coding. However, despite this progress, even the most ...